Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 11, 2008, Pages 1247-1253

  Pan, Ke ^a   Wang, Hui ^a   Chen, Min Shan ^a   Zhang, Hua Kun ^a   Weng, De Sheng ^a   Zhou, Jun ^a   Huang, Wei ^a   Li, Jian Jun ^a   Song, Hai Feng ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Hepatocellular carcinoma (HCC); IDO expression; Indoleamine 2,3 dioxygenase (IDO); Prognostic indicator

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE;

ADULT; ARTICLE; CANCER CELL; CANCER SURVIVAL; CANCER TISSUE; CLINICAL INDICATOR; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 53749088471     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0395-1     Document Type: Article

References (29)

1. S Astigiano B Morandi R Costay L Mastracciz A D'Agostino GB Rattob G Melioli G Frumento 2005 Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung Cancer Neoplasia 7 390 396
2. G Brandacher A Perathoner R Ladurner S Schneeberger P Obrist C Winkler ER Werner G Werner-Felmayer HG Weiss G Gobel R Margreiter A Konigsrainer D Fuchs A Amberger 2006 Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clin Cancer Res 12 1144 1151
3. LM Coussens Z Werb 2002 Inflammation and cancer Nature 420 860 867
4. A Curti S Pandolfi B Valzasina M Aluigi A Isidori E Ferri V Salvestrini G Bonanno S Rutella I Durelli AL Horenstein F Fiore M Massaia MP Colombo M Baccarani RM Lemoli 2007 Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood 109 2871 2877
5. F Fallarino U Grohmann KW Hwang C Orabona C Vacca R Bianchi ML Belladonna MC Fioretti ML Alegre P Puccetti 2003 Modulation of tryptophan catabolism by regulatory T cells Nat Immunol 4 1206 1212
6. F Fallarino U Grohmann S You BC McGrath DR Cavener C Vacca C Orabona R Bianchi ML Belladonna C Volpi P Santamaria MC Fioretti P Puccetti 2006 The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells J Immunol 176 6752 6761
7. EB Finger JA Bluestone 2002 When ligand becomes receptor-tolerance via B7 signaling on DCs Nat Immunol 3 1056 1057
8. M Friberg R Jennings M Alsarraj S Dessureault A Cantor M Extermann AL Mellor DH Munn SJ Antonia 2002 Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection Int J Cancer 101 151 155
9. U Grohmann C Orabona F Fallarino C Vacca F Calcinaro A Falorni P Candeloro ML Belladonna R Bianchi MC Fioretti P Puccetti 2002 CTLA-4-Ig regulates tryptophan catabolism in vivo Nat Immunol 3 1097 1101
10. K Ino N Yoshida H Kajiyama K Shibata E Yamamoto K Kidokora N Takahashi M Terauchi A Nawa S Nomura T Nagasaka O Takikawa F Kikkawa 2006 Indoleamine 2,3-dioxygenase is a novel prognostic indicator for dendometrial cancer B J Cancer 95 1555 1561
11. JR Lee RR Dalton JL Messina MD Sharma DM Smith RE Burgess F Mazzella SJ Antonia AL Mellor DH Munn 2003 Pattern of recruitment of immunoregulatory antigen presenting cells in malignant melanoma Lab Invest 83 1457 1466
12. JH Lee H Torisu-Itakara AJ Cochran A Kadison Y Huynh DL Morton R Essner 2005 Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes Clin Cancer Res 11 107 112
13. MJ Mapara M Sykes 2004 Tolerance and cancer mechanisms of tumor evasion and strategies for breaking tolerance J Clin Oncol 22 1136 1151
14. AL Mellor DH Munn 1999 Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20 169 473
15. AL Mellor DH Munn 2004 IDO expression by dendritic cells: tolerance and tryptophan catabolism Nat Rev Immunol 4 762 774
16. DH Munn AL Mellor 2007 Indoleamine 2,3-dioxygenase and tumor-induced tolerance J Clin Invest 117 1147 1154
17. DH Munn E Shafizadeh JT Attwood I Bondarev A Pashine AL Mellor 1999 Inhibition of T cell proliferation by macrophage tryptophan catabolism J Exp Med 189 1363 1372
18. DH Munn MD Sharma AL Mellor 2004 Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells J Immunol 172 4100 4110
19. DH Munn MD Sharma D Hou B Baban JR Lee SJ Antonia JL Messina P Chandler PA Koni AL Mellor 2004 Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 280 290
20. DH Munn MD Sharma JR Lee KG Jhaver TS Johnson DB Keskin B Marshall P Chandler SJ Antonia R Burgess Jr CL Slingluff AL Mellor 2002 Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 297 1867 1870
21. T Nakamura T Shima A Saeki T Hidaka A Nakashima O Takikawa S Saito 2007 Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer Cancer Sci 98 874 881
22. A Okamoto T Nikaido K Ochiai S Takakura M Saito Y Aoki N Ishii N Yanaihara K Yamada O Takikawa R Kawaguchi S Isonishi T Tanaka M Urashima 2005 Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells Clin Cancer Res 11 6030 6039
23. C Orabona P Puccetti C Vacca S Bicciato A Luchini F Fallarino R Bianchi E Velardi K Perruccio A Velardi V Bronte MC Fioretti U Grohmann 2006 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells Blood 107 2846 2854
24. DM Parkin F Bray J Ferlay P Pisani 2001 Estimating the world cancer burden: Globocan 2000 Int J Cancer 94 153 156
25. O Takikawa R Yoshida R Kido O Hayaishi 1986 Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase J Biol Chem 261 3648 3653
26. ZY Tang 2000 Hepatocellular carcinoma J Gastroenterol Hepatol 15 Suppl 1 7
27. C Uyttenhove L Pilotte I Theate V Stroobant D Colau N Parmentier T Boon BJ Van den Eynde 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 1269 1274
28. MS von Bergwelt-Baildon A Popov T Saric J Chemnitz S Classen MS Stoffel F Fiore U Roth M Beyer S Debey C Wickenhauser FG Hanisch JL Schultze 2006 CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood 108 228 237
29. W Zou 2005 Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 263 274